A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors | MicrobiomeTrials
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2020-10-08Est. Completion: 2022-11-16
Enrollment target: 210 participants
Locations
Organizacion Medica de Investigacion (OMI), Ciudad Autonoma Buenos Aires, Argentina
*X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo André, São Paulo, Brazil
Beneficencia Portuguesa de Sao Paulo, São Paulo, Brazil
Peking Union Medical College Hospital, Beijing, China
Nanfang Hospital, Southern Medical University, Guangzhou, China
The First Affiliated Hospital, Zhejiang University, Hangzhou, China
Jiangsu Province Hospital, Nanjing, China
Affiliated Hospital of Nantong University, Nantong, China
Huashan Hospital, Fudan University, Shanghai, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
Centre Hospitalier Lyon Sud, Pierre-Bnite, Rhone, France
Hopital Claude Huriez - CHU Lille, Lille, France
Universitaetsklinkm, Essen, Germany
Universitaetsklinikum Ulm, Ulm, Germany
General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki, Greece
Sapporo Medical University Hospital, Hokkaido, Japan
Other microbiome trials you might be interested in